Prosecution Insights
Last updated: April 19, 2026
Application No. 17/769,631

EPOXYAMIDES AS KRAS G12C AND KRAS G12D INHIBITORS AND METHODS OF USING THE SAME

Final Rejection §112
Filed
Apr 15, 2022
Examiner
JOHNSON, CHRISTOPHER LINDSAY
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Amgen, Inc.
OA Round
2 (Final)
47%
Grant Probability
Moderate
3-4
OA Rounds
3y 4m
To Grant
99%
With Interview

Examiner Intelligence

Grants 47% of resolved cases
47%
Career Allow Rate
8 granted / 17 resolved
-12.9% vs TC avg
Strong +82% interview lift
Without
With
+81.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
39 currently pending
Career history
56
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
35.6%
-4.4% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
30.7%
-9.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 17 resolved cases

Office Action

§112
DETAILED ACTION This office action is in response to the Applicant’s filing dated December 16th, 2025. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-6, 8, 14, 21, 25, 32-33, 47, 68-73, 75, 83-84 and 120-131 are pending in the instant application. Acknowledgement is made of Applicant’s remarks and amendments filed December 16th, 2025. Acknowledgement is made of applicant’s amendment of claims 1, 8, 14, 21, 25, 33, 47 and 68; cancellation of claims 93-94; and addition of new claims 120-131. Priority This application is a 371 of PCT/US2020/056874 filed on October 22nd, 2020; and a PRO of 62/925,657 filed on October 24th, 2019. Objections and/or Rejections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Objections and/or Rejections) or newly applied (New Objections and/or Rejections, Necessitated by Amendment or New Objections and/or Rejections, NOT Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. New Objections and/or Rejections Necessitated by Claim Amendment Claim Objections Claim 1 is objected to because of the following informalities: The structure representing R3 on page 3, line 6 “ PNG media_image1.png 200 400 media_image1.png Greyscale ” is objected to because on page 4, line 21 the claim further recites “R5a and R6a are absent when b is a double bond”; however, “b” is not present in R3 of claim 1. Appropriate correction is required. Claim 84 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim 120 is objected to because of the following informalities: The recitation of “-C1-6alkyl”, as shown below in claim 120 on page 15 line 13, is improper. Example: PNG media_image2.png 44 188 media_image2.png Greyscale . There should be a space in between the subscript and the next word, and should read “-C1-6 alkyl”. This type of error is repeated several times throughout the claim. Appropriate correction is required. Claim 124 is objected to because of the following informalities: There is duplicate claim numbering present for claim 124 on page 16. Appropriate correction is required. Specification The disclosure is objected to because of the following informalities: the synthetic pathway shown for the process of making (e.g. newly added synthesis claims 125-131) the claimed compounds in the specification is illegible (page 67, paragraph [0259]. Below is an image showing many of the issues exemplified with arrows. Appropriate correction is required. PNG media_image3.png 672 642 media_image3.png Greyscale Maintained Objections and/or Rejections Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 75 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 75 recites the limitation of a structural variable “M” within a chemical structure as shown below in several instances throughout the claim: PNG media_image4.png 200 169 media_image4.png Greyscale The application as filed does not provide any definition or description of “M” in the specification or the claims. The absence of a definition of “M” renders the scope of the claim uncertain. One of ordinary skill in the art would not be able to determine, with reasonable certainty, the scope of the subject matter encompassed by the claim. Applicant argues: “M” is not a structural variable but a stereochemical descriptor that identifies which atropisomer of a molecule with axial chirality is claimed. Examiner's response: The above argument has been carefully considered and has not been found persuasive. While the specification generically states that compounds may exist as atropisomers (page 10, paragraph [0036]), it does not define or explain the “M” stereochemical designation depicted. Accordingly, it is unclear whether the compounds are limited to a particular atropisomer, encompasses all atropisomers, or whether the “M” designation is merely illustrative. As a result, the scope of the claims can’t be determined with reasonable certainty. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: In a search of the claimed compounds, composition comprising of, and process of making compounds of Formula (I), the compounds, composition comprising of, and process of making compounds of Formula (I) were found to be free of prior art. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a). Conclusion Claim 75 is rejected. Claims 1, 84, 120 and 124 are objected to. Claims 2-6, 8, 14, 21, 25, 32-33, 47, 68-73, 83, 121-123 and 125-131 are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L JOHNSON whose telephone number is (571)272-1672. The examiner can normally be reached Monday - Friday 08:00AM - 5:00PM EST with Flex on Fridays. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.L.J./Examiner, Art Unit 1691 /YIH-HORNG SHIAO/Primary Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Apr 15, 2022
Application Filed
Jul 11, 2025
Non-Final Rejection — §112
Dec 16, 2025
Response Filed
Jan 07, 2026
Final Rejection — §112
Apr 08, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12516054
PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Jan 06, 2026
Patent 12485123
1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
2y 5m to grant Granted Dec 02, 2025
Patent 12478613
NOVEL SELECTIVE MAO-B INHIBITOR DRG-MAOB-2 FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES
2y 5m to grant Granted Nov 25, 2025
Patent 12384794
QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN
2y 5m to grant Granted Aug 12, 2025
Patent 12304905
PHARMACEUTICAL SALTS OF BENZOTHIAZOL COMPOUNDS, POLYMORPHS AND METHODS FOR PREPARATION THEREOF
2y 5m to grant Granted May 20, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
47%
Grant Probability
99%
With Interview (+81.8%)
3y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 17 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month